Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BMY

Turn Bristol-Myers Squibb into an Income Machine with This Options Play

With markets coming in to a volatile time of year, investors might be more interested in generating income rather than capital gains.

Barchart

The $400 Billion Reason Bristol-Myers Squibb (BMY) Stock Is Up Today

Bristol-Myers stock extends gains on reports of a potential merger with AstraZeneca. But caution is warranted in chasing the momentum in BMY shares today.

Barchart

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

As per a media report over the weekend, AstraZeneca Plc (NYSE:AZN) and Bristol Myers Squibb Co. (NYSE:BMY) are in potential discussions to form a pharmaceutical giant valued at nearly $400 billion.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Bristol-Myers Squibb Stock: Analyst Estimates & Ratings

Bristol-Myers Squibb has rallied the broader market over the past year, and analysts remain moderately bullish about the stock’s prospects.

Barchart

Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now

As investors rotate toward value, Altria, Bristol Myers Squibb, and American Electric Power stand out as reliable dividend stocks with strong payout growth histories and defensive appeal.

MarketBeat

Bristol-Myers Squibb’s Q2 2026 Earnings: What to Expect

Bristol-Myers Squibb is expected to report its second-quarter earnings later this month, and Wall Street is calling for a double-digit decrease in profit.

Barchart

Is Bristol-Myers Squibb Stock Underperforming the Dow?

Bristol-Myers Squibb has underperformed the Dow recently, yet analysts remain moderately optimistic about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Bristol-Myers Squibb Stock Rises on Anthropic AI Deal. Why This Could Actually Be a Key Upside Catalyst.

BMY stock rose after the company announced a strategic AI deal with Anthropic to deploy Claude across its workforce.

Barchart

Bloomsbury Publishing H2 Earnings Call Highlights

Bloomsbury Publishing (LON:BMY) reported higher profit and earnings despite a year-over-year revenue decline, as management pointed to the resilience of its mix of consumer and academic publishing and said it expects to deliver record profit in the current financial year. Founder and Chief Executiv

MarketBeat

Do Wall Street Analysts Like Bristol-Myers Squibb Stock?

Although Bristol-Myers Squibb has lagged behind the SPX over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Bristol-Myers Squibb Earnings Preview: What to Expect

Bristol-Myers Squibb is approaching its first-quarter earnings release this month, and Wall Street is forecasting a double-digit percentage fall in earnings.

Barchart

Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Barchart

Stocks Retreat as Tech Stocks Fall and the US Labor Market Weakens

The S&P 500 Index ($SPX ) (SPY ) today is down -1.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.49%. March E-mini S&P futures (ESH26 ) are down -1.29%, and March E-mini Nasdaq futures...

Barchart

Bristol-Myers Squibb Stock Outlook: Is Wall Street Bullish or Bearish?

Bristol-Myers Squibb has lagged the broader market over the past year, but analysts are growing optimistic about the company’s outlook.

Barchart

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

2 Buffett Stocks to Load Up On—And 1 to Ditch

With Buffett having officially stepped down at Berkshire Hathaway, investors might continue to follow his lead when it comes to these popular names.

Barchart

What You Need To Know Ahead of Bristol-Myers Squibb's Earnings Release

Bristol-Myers Squibb is poised to announce its fourth-quarter results next month, and analysts predict a single-digit decline in the company’s bottom-line figure.

Barchart

The Healthcare Sector is Gaining Momentum. Watch This Stock Chart for a Reversal Setup.

Our top chart strategist is tracking a 3-candle drop pattern on AHR.

Benzinga

BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co. (NYSE:BMY) on Tuesday shared the first interim data from a global randomized Phase 2 trial of pumitamig (BNT327/BMS986545) plus chemotherapy for locally advanced/metastatic triple-negative breast cancer (TNBC) irrespective of PD-L1 expression levels.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Bristol Myers Pushes Data Readout For Key Alzheimer's Psychosis Study After Irregularities

Bristol Myers Squibb Co. (NYSE:BMY) on Wednesday said it would enroll additional patients in the ADEPT-2 Phase 3 study.

Barchart

Is Bristol-Myers Stock Underperforming the S&P 500?

Bristol-Myers has lagged behind the broader S&P 500 Index, and Wall Street remains cautious about this stock.

Benzinga

Bayer Stroke Drug Hits Trial Goals, Analyst Sees Positive Data Readout From Bristol Myers' Milvexian After Failed Study

Bayer AG (OTC:BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian.

Benzinga

Bristol Myers Faces Another Trial Disappointment As Heart Drug Milvexian Fails To Show Efficacy

Bristol Myers Squibb Co. (NYSE:BMY), in collaboration with Johnson Johnson (NYSE:JNJ), announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS)…

Barchart

Two Straddles Define Wednesday’s Unusual Options Activity Across Key Stocks

Among Wednesday’s 35 most unusually active options, two emerged as notable straddle setups appealing to both bullish and bearish traders. These potential plays revolve around some of the market’s most familiar and widely followed stocks.

Barchart

Are Wall Street Analysts Predicting Bristol-Myers Squibb Stock Will Climb or Sink?

Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

Barchart

The Saturday Spread: Using the ‘Taxonomical’ Approach to Extract Profits

While fundamental and technical analyses dominate the finance ecosystem, there’s another, more powerful mechanism to succeed in the markets.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.